Sinforiani E, Iannuccelli M, Mauri M, Costa A, Merlo P, Bono G, Nappi G
Department of Neurology 3rd, University of Pavia, Italy.
Int J Clin Pharmacol Res. 1990;10(1-2):69-74.
The study was carried out on 24 patients suffering from mild to moderate dementia. The diagnosis of dementia was made according to DMS III criteria. Patients with cerebrovascular pathologies were excluded by using Hachinski Ischaemic Score less than or equal to 4 and computerized tomography parameters. Patients with depression (Hamilton Rating Scale for Depression greater than or equal to 18) were excluded. All the patients, after a wash-out period of two weeks were treated on a simple blind method with acetyl-L-carnitine (No. = 12 patients) and piracetam (12 patients) by intravenous route (two weeks) followed by an oral one for further 10 weeks. A battery of clinical neuropsychological tests was applied to evaluate the cognitive, attentive and behavioural aspects. The results, analysed by non-parametric variance analysis (Friedman Test) show a statistically significant improvement of the behavioural profile, of attention and of psychomotricity in the patients treated with acetyl-L-carnitine. No significant improvement was found in the piracetam group.
该研究对24例轻至中度痴呆患者进行。痴呆的诊断依据DMS III标准。通过使用哈金斯基缺血评分小于或等于4以及计算机断层扫描参数排除脑血管疾病患者。排除抑郁患者(汉密尔顿抑郁量表评分大于或等于18)。所有患者在经过两周的洗脱期后,采用单盲法通过静脉途径(两周)给予乙酰-L-肉碱(12例患者)和吡拉西坦(12例患者)治疗,随后口服给药10周。应用一系列临床神经心理学测试来评估认知、注意力和行为方面。通过非参数方差分析(弗里德曼检验)分析的结果显示,接受乙酰-L-肉碱治疗的患者在行为特征、注意力和精神运动能力方面有统计学上的显著改善。在吡拉西坦组未发现显著改善。